NCT04862338View on ClinicalTrials.gov

Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

September 8, 2021

Study Completion Date

April 4, 2022

Conditions
Healthy Volunteers
Interventions
DIETARY_SUPPLEMENT

Nicotinamide mononucleotide (NMN-C)

Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total

Trial Locations (1)

21000

Biomed 21, Dijon

Sponsors

Collaborators (1)

CEN Biotech
All Listed Sponsors
collaborator

CEN Biotech

INDUSTRY

collaborator

LGD

INDUSTRY

lead

Seneque SA

INDUSTRY

NCT04862338 - Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults | Biotech Hunter | Biotech Hunter